Boceprevir Patent Expiration
Boceprevir is Used for treating chronic Hepatitis C genotype 1 infection in adult patients with compensated liver disease. It was first introduced by Merck Sharp And Dohme Corp
Boceprevir Patents
Given below is the list of patents protecting Boceprevir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Victrelis | US7772178 | Pharmaceutical formulations and methods of treatment using the same | Nov 11, 2027 | Merck Sharp Dohme |
| Victrelis | US8119602 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | Mar 17, 2027 | Merck Sharp Dohme |
| Victrelis | USRE43298 | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
Dec 22, 2024
(Expired) | Merck Sharp Dohme |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Boceprevir's patents.
Latest Legal Activities on Boceprevir's Patents
Given below is the list recent legal activities going on the following patents of Boceprevir.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 12 Sep, 2022 | US7772178 |
| Maintenance Fee Reminder Mailed Critical | 28 Mar, 2022 | US7772178 |
| Expire Patent Critical | 30 Mar, 2020 | US8119602 |
| Maintenance Fee Reminder Mailed Critical | 14 Oct, 2019 | US8119602 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2018 | US7772178 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Feb, 2012 | US8119602 |
| Recordation of Patent Grant Mailed Critical | 21 Feb, 2012 | US8119602 |
| Issue Notification Mailed Critical | 01 Feb, 2012 | US8119602 |
| Dispatch to FDC | 03 Jan, 2012 | US8119602 |
| Petition Decision - Dismissed Critical | 22 Dec, 2011 | US8119602 |
Boceprevir's Family Patents
